Implications for the future of the HIV epidemic if drug resistance against dolutegravir cannot occur in first-line therapy

Journal of the International AIDS Society

Volumn 18, Issue 1, 2015, Pages

  Wainberg, Mark A ^a   Mesplede, Thibault ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DOLUTEGRAVIR; ELVITEGRAVIR; EMTRICITABINE; LAMIVUDINE; RALTEGRAVIR;

ANTIVIRAL THERAPY; CLINICAL TRIAL (TOPIC); CROSS RESISTANCE; DRUG TREATMENT FAILURE; EPIDEMIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NOTE; PRIORITY JOURNAL; THERAPY RESISTANCE; VIRUS LOAD; VIRUS MUTATION;

EID: 84959192276     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.7448/IAS.18.1.20824     Document Type: Note

References (22)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents [Internet]. 2013 [cited 2013 Dec 10]. Available from: http://aidsinfo.nih.gov/guidelines
2. Clotet B, Feinberg J, van Lunzen J, Khuong-Josses MA, Antinori A, Dumitru I, et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviralnaive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet. 2014;383(9936):2222-31.
3. Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutierrez F, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369(11):1807-18.
4. Raffi F, Jaeger H, Quiros-Roldan E, Albrecht H, Belonosova E, Gatell JM, et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2013; 13(11):927-35.
5. Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013;381(9868):735-43.
6. Smith RA, Raugi DN, Pan C, Sow PS, Seydi M, Mullins JI, et al. In vitro activity of dolutegravir against wild-Type and integrase inhibitor-resistant HIV-2. Retrovirology. 2015;12:10.
7. Descamps D, Peytavin G, Visseaux B, Tubiana R, Damond F, Campa P, et al. Dolutegravir in HIV-2-infected patients with resistant virus to first-line integrase inhibitors from the French named patient program. Clin Infect Dis. 2015;60(10):1521-7.
8. Donnell DJ, Hall HI, Gamble T, Beauchamp G, Griffin AB,Torian LV, et al. Use of HIV case surveillance system to design and evaluate site-randomized interventions in an HIV prevention study: HPTN 065. Open AIDS J. 2012;6:122-30.
9. Simoni JM, Frick PA, Lockhart D, Liebovitz D. Mediators of social support and antiretroviral adherence among an indigent population in New York City. AIDS Patient Care STDS. 2002;16(9):431-9.
10. Garland WH,Wohl AR, Valencia R, Witt MD, Squires K, Kovacs A, et al. The acceptability of a directly-Administered antiretroviral therapy (DAART) intervention among patients in public HIV clinics in Los Angeles, California. AIDS Care. 2007;19(2):159-67.
11. Cohn J, Bekker L-G, Bygrave H, Calmy A. Hit me with your best shot: dolutegravir-A space in the next WHO guidelines? AIDS. 2015;29(16):2067-70.
12. Castagna A, Maggiolo F, Penco G, Wright D, Mills A, Grossberg R, et al. Dolutegravir in antiretroviral-experienced patients with raltegravir-And/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis. 2014;210(3):354-62.
13. Eron JJ, Clotet B, Durant J, Katlama C, Kumar P, Lazzarin A, et al. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravirresistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis. 2013;207(5):740-8.
14. Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet. 2013;382(9893): 700-8.
15. Mesplede T, Quashie PK, Osman N, Han Y, Singhroy DN, Lie Y, et al. Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. Retrovirology. 2013;10:22-8.
16. Quashie PK, Oliviera M, Veres T, Osman N, Han YS, Hassounah S, et al. Differential effects of the G118R, H51Y, and E138K resistance substitutions in different subtypes of HIV integrase. J Virol. 2015;89(6):3163-75.
17. Wainberg MA, Mesplede T, Raffi F. What if HIV were unable to develop resistance against a new therapeutic agent? BMC Med. 2013;11(1):249-54.
18. Figueroa MI, Sued O, Patterson P, Gun A, Rolon M, Cahn P. Dolutegravirlamivudine as initial therapy in HIV-infected, ARV naive patients: first results of the PADDLE trial. 15th European AIDS Conference; 2015 Oct 21-24; Barcelona, Spain; 2015.
19. Rojas J, Blanco J, Lonca M,Torres B, PareraM, Gonzalez A, et al. Dolutegravir monotherapy in HIV-infected patients with sustained viral suppression: A 24-week pilot study. 15th European AIDS Conference; 2015 Oct 21-24; Barcelona, Spain; 2015.
20. Katlama C, Soulie C, Blanc C, Denis A, Caby F, Schneider L, et al. Dolutegravir monotherapy in patients with suppressed HIV viremia. 15th European AIDS Conference; 2015 Oct 21-24; Barcelona, Spain; 2015.
21. Akil B, Blick G, Hagins DP, Ramgopal MN, Richmond GJ, Samuel RM, et al. Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study. Antivir Ther. 2015;20(3):343-8.
22. Mesplede T, Wainberg MA. Resistance against integrase strand transfer inhibitors and relevance to HIV persistence. Viruses. 2015;7(7):3703-18.